Alkermes Sells Lybalvi Rights to Sumitomo for $200M
Ticker: ALKS · Form: 8-K · Filed: Apr 16, 2025 · CIK: 1520262
| Field | Detail |
|---|---|
| Company | Alkermes PLC. (ALKS) |
| Form Type | 8-K |
| Filed Date | Apr 16, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: divestiture, licensing, pharmaceuticals, deal
Related Tickers: SUMTF
TL;DR
Alkermes sells Lybalvi US rights to Sumitomo for $200M upfront, focusing on pipeline.
AI Summary
Alkermes plc. announced on April 14, 2025, that it has entered into a definitive agreement to sell its U.S. commercial rights to the schizophrenia drug Lybalvi to Sumitomo Pharma Co., Ltd. for an upfront payment of $200 million. Alkermes will also receive potential milestone payments and royalties on net sales, with the transaction expected to close in the second half of 2025.
Why It Matters
This divestiture allows Alkermes to focus on its pipeline and potentially accelerate the development of new therapies, while Sumitomo gains a commercial foothold in the U.S. for a key schizophrenia treatment.
Risk Assessment
Risk Level: medium — The transaction's success depends on regulatory approvals and Sumitomo's ability to commercialize Lybalvi effectively, with potential risks related to milestone achievement and royalty streams.
Key Numbers
- $200.0M — Upfront Payment (Received by Alkermes from Sumitomo Pharma for U.S. commercial rights to Lybalvi.)
Key Players & Entities
- Alkermes plc. (company) — Seller of U.S. commercial rights
- Sumitomo Pharma Co., Ltd. (company) — Buyer of U.S. commercial rights
- Lybalvi (drug) — Schizophrenia drug
- $200 million (dollar_amount) — Upfront payment for U.S. commercial rights
- April 14, 2025 (date) — Date of definitive agreement
- second half of 2025 (date) — Expected closing period for the transaction
FAQ
What specific U.S. commercial rights to Lybalvi is Alkermes selling?
Alkermes is selling its U.S. commercial rights to Lybalvi, a drug for schizophrenia.
What is the total potential value of the deal for Alkermes?
The deal includes an upfront payment of $200 million, plus potential future milestone payments and royalties on net sales.
When is the transaction expected to be completed?
The transaction is expected to close in the second half of 2025.
What is the primary therapeutic area for Lybalvi?
Lybalvi is indicated for the treatment of schizophrenia.
What is Alkermes' strategic rationale for this sale?
Alkermes intends to use the proceeds to focus on its pipeline and accelerate the development of new therapies.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 16, 2025 regarding Alkermes plc. (ALKS).